Multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of three different doses (275, 550 AND 1100 mg) of rifaximin [XIFAXIN] administered BID [twice-daily] for either two or four weeks in the treatment of patients with diarrhea-associated irritable bowel syndrome

Trial Profile

Multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of three different doses (275, 550 AND 1100 mg) of rifaximin [XIFAXIN] administered BID [twice-daily] for either two or four weeks in the treatment of patients with diarrhea-associated irritable bowel syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2015

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Bacterial infections; Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Salix Pharmaceuticals
  • Most Recent Events

    • 07 Oct 2008 Results presented at the American College of Gastroenterology.
    • 03 Oct 2008 Results presented at ACG 2008.
    • 20 May 2008 Top-line results reported in a Salix Pharmaceuticals media release (9090646).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top